Ottawa’s net-zero advisory co-chair resigns, citing disappointment with climate priorites

Health Canada has approved the first drug specifically developed to treat moderate to severe postpartum depression, a condition affecting roughly one in five women in Canada. ZURZUVAE, also known as zuranoline, is a 14-day treatment that helps the brain restore its natural balance between calming and activating signals. Clinical trials have reported to show improvements as early as day three, a significant reduction in symptoms by day 15 and a sustained effect by day 45, in contrast to a placebo. Patients with ZURZUVAE showed an average reduction of 17.8 points while those with a...